Bacteroides cellulosilyticus-directed glycans relieve colitis

Bacteroides cellulosilyticus correlates with inflammatory bowel disease (IBD). Targeting an increase in abundance of B. cellulosilyticus is a feasible approach to treating IBD. Although B. cellulosilyticus is responsive to dietary components, untargeted manipulation cannot focus on target microbe and can lead to an increase in harmful bacteria in the microbiota. Despite breakthroughs in methods for regulating specific microbes, the protocols are expensive, time-consuming, and difficult to follow. Glycans based on microbial-carbohydrate-active enzymes (CAZymes) that target a specific microbiota would provide a potential solution.解纤维素拟杆菌（Bacteroides cellulosilyticus）与炎症性肠病（IBD）密切相关。靶向提升该菌的丰度，是治疗炎症性肠病的可行方案。尽管解纤维素拟杆菌可响应膳食成分，但非靶向调控无法精准靶向目标微生物，还可能导致菌群内有害菌丰度升高。尽管特异性微生物调控方法已取得突破，但相关实验方案成本高昂、耗时较长且操作难度较大。以靶向特定微生物群的微生物碳水化合物活性酶（CAZymes）为基础制备的聚糖，或将成为一种潜在的治疗解决方案。